<?xml version="1.0" encoding="UTF-8"?>
<p>Signed concurrently with the establishment of the World Trade Organization (WTO) in 1994, the TRIPS Agreement sought to create a global intellectual property rights regime that would harmonize legal standards across WTO member states [
 <xref rid="R2" ref-type="bibr">2</xref>]. Prior to the TRIPS Agreement, many countries excluded pharmaceutical products from patentability in order to ensure drug prices were affordable. India and Brazil, for example, had previously only allowed for process patents and not product patents [
 <xref rid="R3" ref-type="bibr">3</xref>]. This permitted domestic generic pharmaceutical companies to reverse-engineer and produce bioequivalent drugs.
</p>
